Cullinan Therapeutics (CGEM) Return on Capital Employed (2021 - 2026)

Cullinan Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 61.55% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 2511.0% year-over-year to 61.55% in Q1 2026; TTM through Mar 2026 was 61.55%, a 2511.0% decrease from a year earlier, with the FY2025 full-year figure at 48.59%, down 1089.0% from the prior year.
• Return on Capital Employed declined to 61.55% in Q1 2026 per CGEM's latest filing, from 56.39% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 31.47% in Q2 2022 and bottomed at 61.55% in Q1 2026.
• The 5-year median for Return on Capital Employed is 33.91% (2024), against an average of 24.54%.
• Biggest YoY gain for Return on Capital Employed was 4666 bps in 2023; the steepest drop was 6695 bps in 2023.
• Year by year, Return on Capital Employed stood at 25.53% in 2022, then sank by 262 bps to 41.42% in 2023, then increased by 22 bps to 32.45% in 2024, then slumped by 74 bps to 56.39% in 2025, then fell by 9 bps to 61.55% in 2026.
• Per Business Quant, the three latest CGEM Return on Capital Employed figures stand at 61.55% (Q1 2026), 56.39% (Q4 2025), and 51.43% (Q3 2025).